

In re: Whitehouse
Appl. No.: 09/802,365
Filed: March 9, 2001
Page 3 of 11

In the Claims:

Please cancel claims 3 and 18.

Please amend claims 1, 4, 6, 16, 19, and 21 to read as follows:

A3
1. (amended) A method for treating or preventing erectile dysfunction in a patient, said method comprising administering to said patient a therapeutically effective amount of a growth factor, wherein said growth factor is fibroblast growth factor (FGF).

A4
4. (amended) The method of claim 2, wherein said FGF is FGF-2.

A5
6. (amended) The method of claim 5, wherein said FGF-2 comprises the sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or a biologically active fragment or mutein thereof.

A6
16. (amended) A method for improving erectile function in a mammal, said method comprising delivering at a target site in said mammal in a therapeutically effective amount a pharmaceutical composition, said composition comprising fibroblast growth factor (FGF) and a pharmaceutically acceptable carrier.

A7
19. (amended) The method of claim 17, wherein said FGF is FGF-2.

A8
21. (amended) The method of claim 19, wherein said FGF-2 comprises the sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or a biologically active fragment or mutein thereof.

REMARKS

Claims 3 and 18 have been canceled subject to the restriction of independent claims 1 and 16 to the single growth factor FGF. Claims 1, 6, 16, and 21 have been amended to remove subject matter drawn to non-elected inventions. Claims 4 and 19 have been amended so that they do not refer to a canceled claim. No new matter has been added by way of claim amendment. Entry of these claim amendments into the above-referenced application is respectfully requested. Applicant expressly reserves the right to pursue this canceled subject